Plasma levels of the coagulation inhibitors antithrombin and protein C have been shown to decrease, while tissue factor (TF) pathway inhibitor (TFPI) was found to increase during cancer progression[8, 9], and several studies have shown that cancer patients acquire activated protein C (APC) resistance[2, 3, 10, 11]. This evidence concerns the gene TFPI and cancer.